Colorectal cancer (CRC) is a major health concern worldwide, characterized by high incidence and mortality rates. Despite advances in treatment, metastatic CRC (mCRC) remains particularly challenging.
Jul 1, 2024
0
2
A new editorial paper titled "One more step toward treatment of PARP inhibitor-resistant ovarian cancers" has been published in Oncotarget.
Jan 10, 2024
0
2
A new research paper was published in Oncotarget, titled, "Effectiveness and toxicity of cetuximab with concurrent RT in locally advanced cutaneous squamous cell skin cancer: a case series."
Jul 14, 2023
0
8
Long-term follow up of patients with extensive stage small cell lung cancer who were given pembrolizumab and etoposide/platinum (EP) versus placebo + etoposide/platinum as first-line therapy support the continued exploration ...
Aug 9, 2022
0
7
Patients with metastatic non-small cell lung cancer who received a combined therapy of tremelimumab, durvalumab and chemotherapy experienced longer overall survival compared with those who received chemotherapy alone, regardless ...
Aug 9, 2022
0
2
In the initial NADIM trial, neoadjuvant chemoimmunotherapy was shown to be highly effective in patients with resectable stage IIIA non-small cell lung cancer. Today, the researchers from the NADIM trial present new data ...
Aug 8, 2022
0
15
The human monoclonal antibody sugemalimab is a safe and effective consolidation therapy for patients with unresectable stage III non-small cell lung cancer without disease progression after either concurrent chemoradiotherapy ...
Aug 8, 2022
0
2
Results of a biomarker analysis of the NRG Oncology NRG-GY004 trial were presented at a Seminal Session during the Society for Gynecologic Oncology's (SGO) Annual Meeting on Women's Cancer in March 2022. The analysis, which ...
Mar 21, 2022
0
4
Long-term survival data from the first prospective, randomized biomarker validation trial in patients with muscle-invasive bladder cancer being treated with cisplatin-based chemotherapy before surgery will be reported at ...
Feb 14, 2022
0
6
(HealthDay)—STRIDE (Single tremelimumab Regular Interval durvalumab) is proposed as first-line therapy for unresectable hepatocellular carcinoma (uHCC), according to a study presented at the annual American Society of Clinical ...
Jan 24, 2022
0
46
